| Combination of | |
|---|---|
| Tretinoin | Retinoid |
| Benzoyl peroxide | Oxidizing agent |
| Clinical data | |
| Trade names | Twyneo |
| Other names | S6G5T-3 |
| License data | |
|
Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Tretinoin/benzoyl peroxide, sold under the brand name Twyneo, is a fixed-dose combination medication used for the treatment of acne. [1] [2] It contains tretinoin, a vitamin A derivative, and benzoyl peroxide, an oxidizing agent. [3]
The combination was approved for medical use in the United States in July 2021. [2] [4] [5]
References
- ^ a b "Twyneo (tretinoin and benzoyl peroxide) cream, for topical use" (PDF). U.S. Food and Drug Administration.
- ^ a b "Sol-Gel Technologies Announces FDA Approval of Twyneo" (Press release). Sol-Gel Technologies Ltd. 27 July 2021. Retrieved 27 July 2021 – via GlobeNewswire.
- ^ Ochsendorf F (June 2015). "Clindamycin phosphate 1.2% / tretinoin 0.025%: a novel fixed-dose combination treatment for acne vulgaris". Journal of the European Academy of Dermatology and Venereology. 29 (Suppl 5): 8–13. doi: 10.1111/jdv.13185. PMID 26059820. S2CID 29681121.
- ^ "Twyneo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 27 July 2021.
- ^ "NDA Approval: Twyneo" (PDF). U.S. Food and Drug Administration. 26 July 2021.
External links
- "Tretinoin". Drug Information Portal. U.S. National Library of Medicine.
- "Benzoyl peroxide". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03761784 for "A Study of S6G5T-3 in the Treatment of Acne Vulgaris" at ClinicalTrials.gov
- Clinical trial number NCT03761810 for "A Study of S6G5T 3 in the Treatment of Acne Vulgaris" at ClinicalTrials.gov
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |